• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
PVP-K30-----pharma excipients(CAS No.9003-39-8)
Tobramycin
Povidone iodine 20% powder
Povidone iodine 10% powder
SULBACTAM SODIUM STERILE
Food Additives Bulk Sucralose Neotame Advantame Powder

Taiwan, China starts study on efficacy of mixing AZ, Moderna COVID vaccines

firstwordpharmaAugust 02, 2021

Tag: AZ , Moderna , COVID vaccines

A hospital in Taiwan, China has begun a clinical study investigating a mix and match approach with COVID-19 vaccines from AstraZeneca and Moderna, Taiwan, China News reported.

Taiwan, China starts study on efficacy of mixing AZ, Moderna COVID vaccines

The trial, which is being carried out by the National Taiwan, China University Hospital (NTUH), includes four groups of 100 subjects, with the first two receiving doses of AstraZeneca and Moderna's vaccines four or eight weeks apart.

Meanwhile, the third group will receive two doses of AstraZeneca's vaccine eight weeks apart, with the final group given two doses of Moderna's vaccine, also eight weeks apart


Previous:Pfizer and Moderna raise prices for its COVID-19 vaccines in EU

Next:UK scientists believe it is 'almost certain' a coronavirus variant will emerge that beats current vaccines

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Taiwan, China starts study on efficacy of mixing AZ, Moderna COVID vaccines | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxy-propyl]-4-(4-hydroxyphenyl)-azetidin-2-one

1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxy-propyl]-4-(4-hydroxyphenyl)-azetidin-2-one
AZINTAMIDE

AZINTAMIDE
Esomeprazole Magnesium

Esomeprazole Magnesium
2-chloro-4-(4-(naphthalen-2-yl)phenyl)-6-phenyl-1,3,5-triazine

2-chloro-4-(4-(naphthalen-2-yl)phenyl)-6-phenyl-1,3,5-triazine
1-(1-ethoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole

1-(1-ethoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
Azelastine HCl

Azelastine HCl
2-(2-Bromophenyl)-4,6-diphenyl-1,3,5-triazine

2-(2-Bromophenyl)-4,6-diphenyl-1,3,5-triazine
1H-Tetrazol-5-Ethyl Formate

1H-Tetrazol-5-Ethyl Formate
2-(TRIBUTYLSTANNYL)BENZOXAZOLE

2-(TRIBUTYLSTANNYL)BENZOXAZOLE
Carbazochome

Carbazochome

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service